Novo Nordisk offers diabetes drug Ozempic for a steep discount on cash

Novo nordisk On Monday, he said he now proposes to pay us patients, his diabetes treatment at the Azempia blockbuster for less than half a monthly cost in the list, as drug manufacturers face political pressure on price decline.

Patients can pay $ 499 in cash for three ozempic dose sizes. They can get the price through the platforms including the official drug site, the Novo Nordisk Patients’ Assistance Program and the recently launched company Internet Optional ConsumerThe latter also supplies injection directly to patients’ homes.

Goodrx drug savings also offers Ozempic and its Wegovy weight loss counterpart per month, which makes discounts available in more than 70,000 pharmacies across the country, Novo Nordisk Release reports.

“We saw how the rapid demand for our consumer base for these highly sought after treatment, but millions of people are still missing the proper insurance coverage,” said Goodrx Wendy Barnes in a statement. “With this cooperation, we make a significant step forward in our broader efforts to fill in the lighting gaps when insurance is missing.”

The Novo Nordisk Cash Offer will expand access to patients with type 2 diabetes who do not have insurance coverage for weekly injection. In March the company started offering wegovy Half of the cost on the list for Americans who pay cash.

The cost of the Ozempic list before insurance and other discounts is almost $ 1,350 a month, and in recent years was a frequent purpose of political and public excitement. A new proposal comes after the president Donald Trump In July, they sent separate Novo Nordisk letters and 16 other drug manufacturers, calling them to take steps To reduce the cost of medicines in the United States among other proposed actions, he urged them to take models that sell medicines directly to consumers and enterprises.

These efforts are aimed at making Ozempic and Wegovy available to more people, as well as ensuring that patients use branded medicines rather than cheaper copies. These drugs have exploded in popularity during the deficit in the US Novo Nordisk’s Semaglutide, an active ingredient in both drugs.

While Ozempic “well covered in the United States, we will not forget that there are some patients who pay for this vital medicine,” said Dave Moore, the US Operations and Global Business Development in Novo Nordisk, in the release. “We believe that even if one patient feels the need to turn to potentially dangerous and unauthorized alternative alternatives, it’s too much.”

Eli Lily Similarly, it has moved to reduce the price of its popular obesity and diabetes drugs for patients with cash. Both companies are struggling to dominate the so-called GLP-1 market, which mimic certain bowel hormones to suppress the appetite and regulate blood sugar.